Half of Long‑Term Head and Neck Cancer Survivors Report Unmet Supportive Care Needs — A Multinational Cohort Highlights Clinical and System Drivers
Posted innews Oncology Otorhinolaryngology

Half of Long‑Term Head and Neck Cancer Survivors Report Unmet Supportive Care Needs — A Multinational Cohort Highlights Clinical and System Drivers

A multinational cross‑sectional study of 1,097 head and neck cancer survivors >5 years after diagnosis found that ~50% report moderate‑to‑high unmet supportive care needs, driven by HNC‑specific, psychological and physical/daily living concerns and associated with personal, clinical, lifestyle and health‑system factors.
Dutch Nationwide Registry Shows Large Health-System Burden and Early Progression Risk in Advanced Cutaneous Squamous Cell Carcinoma
Posted inDermatology news Oncology

Dutch Nationwide Registry Shows Large Health-System Burden and Early Progression Risk in Advanced Cutaneous Squamous Cell Carcinoma

The Dutch Keratinocyte Cancer Collaborative (DKCC) provides the first nationwide longitudinal real-world dataset of advanced cutaneous squamous cell carcinoma (CSCC), estimating that 8% of CSCC are locally advanced and demonstrating short median times to recurrence or metastasis, substantial resource needs, and meaningful proportions of untreated metastatic episodes.
Rare but Real: Higher Risks of Vascular and Inflammatory Disease After SARS‑CoV‑2 Infection Than After BNT162b2 Vaccination in Children and Adolescents
Posted innews Pediatrics Public Health

Rare but Real: Higher Risks of Vascular and Inflammatory Disease After SARS‑CoV‑2 Infection Than After BNT162b2 Vaccination in Children and Adolescents

A nationwide English cohort study (n≈13.9M) found transient but significant increases in rare vascular and inflammatory events after first SARS‑CoV‑2 infection and a smaller, short-lived increase in myocarditis/pericarditis after first BNT162b2 vaccination—supporting vaccination to reduce greater risks from infection.
Increased Gestational Weight Gain and Adverse Pregnancy Outcomes After Stopping GLP‑1 Receptor Agonists Prior to or in Early Pregnancy
Posted inDiabetes & Endocrinology news

Increased Gestational Weight Gain and Adverse Pregnancy Outcomes After Stopping GLP‑1 Receptor Agonists Prior to or in Early Pregnancy

In a large retrospective cohort, women who discontinued GLP‑1 receptor agonists shortly before or during early pregnancy had greater gestational weight gain and higher risks of preterm birth, gestational diabetes, and hypertensive disorders compared with propensity‑matched unexposed pregnancies.
Bivalent RSV pre‑F Vaccine Dramatically Reduces RSV‑Associated Hospitalisations and Chronic‑Disease Exacerbations in Adults Aged 75–79 Years
Posted inInfectious Diseases news Respiratory

Bivalent RSV pre‑F Vaccine Dramatically Reduces RSV‑Associated Hospitalisations and Chronic‑Disease Exacerbations in Adults Aged 75–79 Years

In a multicentre test‑negative study of 1006 adults aged 75–79 in England, a bivalent RSV pre‑F vaccine reduced RSV‑associated hospitalisation by 82% overall and protected against severe disease and exacerbations of chronic heart and lung disease, including in immunosuppressed patients.
Three-Month Clofazimine–Rifapentine Regimen for Drug‑Susceptible TB Failed to Improve Outcomes and Raised Safety Concerns: Lessons from Clo‑Fast (Phase 2c)
Posted inInfectious Diseases news Respiratory

Three-Month Clofazimine–Rifapentine Regimen for Drug‑Susceptible TB Failed to Improve Outcomes and Raised Safety Concerns: Lessons from Clo‑Fast (Phase 2c)

The Clo‑Fast phase 2c trial tested a 3‑month rifapentine‑clofazimine regimen versus standard 6‑month therapy for drug‑susceptible pulmonary TB. Culture conversion at 12 weeks was similar, but shorter therapy had higher grade ≥3 adverse events and worse 65‑week composite clinical outcomes, leading to early termination.
Orodispersible Ivermectin and Moxidectin–Albendazole Combinations Deliver Major Gains Against Trichuris trichiura in Children: Dose‑response, Safety, and Programmatic Implications
Posted inInfectious Diseases news Pediatrics

Orodispersible Ivermectin and Moxidectin–Albendazole Combinations Deliver Major Gains Against Trichuris trichiura in Children: Dose‑response, Safety, and Programmatic Implications

Two randomized trials from Pemba Island show orodispersible ivermectin–albendazole yields dose‑dependent high cure rates in preschool children, and moxidectin–albendazole is superior to albendazole alone in school‑aged children, both with acceptable safety.
Once-Weekly Navepegritide Raises Growth Velocity and Improves Skeletal and Functional Outcomes in Children with Achondroplasia: Results from the APPROACH Trial
Posted innews Orthopedics Pediatrics

Once-Weekly Navepegritide Raises Growth Velocity and Improves Skeletal and Functional Outcomes in Children with Achondroplasia: Results from the APPROACH Trial

The APPROACH randomized trial found once-weekly navepegritide significantly increased annualized growth velocity and produced favorable skeletal alignment and physical-function improvements in children with achondroplasia, with an acceptable short-term safety profile.
Human Monoclonal Antibody MAM01 for Malaria Prevention: Phase 1 Trial Insights and Context in Antimalarial Monoclonal Antibody Development
Posted inClinical Updates Infectious Diseases news Public Health

Human Monoclonal Antibody MAM01 for Malaria Prevention: Phase 1 Trial Insights and Context in Antimalarial Monoclonal Antibody Development

This review synthesizes evidence on MAM01, a monoclonal antibody targeting Plasmodium falciparum circumsporozoite protein, summarizing its first-in-human phase 1 trial demonstrating safety and protective efficacy, alongside contextual advances in monoclonal antibody-based malaria prevention.